Clinical trials: Pharyngeal Cancer
Oropharyngeal Neoplasms
Human Papillomavirus and Oropharynx Carcinoma
High risk papillomavirus (HR-HPV) have an oncogenic role in Oropharyngeal squamous cell carcinomas (OP-SCC) in at least 25% of the cases and the prevalence is increasing.
- Trial name
- Papillophar (NCT00918710)
- Where
- France
- Volunteers
- 362 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Head and Neck Squamous Cell Carcinoma
BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
Head and neck squamous cell carcinoma (include nasopharyngeal carcinoma) is one of the most common malignant tumor in China, and radiotherapy is the main treatment method.
- Trial name
- NCT05299203
- Testing
- Sapropterin dihydrochloride tablets
- Volunteers
- 18 people
- Sponsor
- West China Hospital
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant
- Trial name
- NCT02734537
- Testing
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 679 sites in United States
- Volunteers
- 189 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Nasopharyngeal Carcinoma
Anrotinib and Tirelizumab in First-line Treatment of RM-NPC
This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05981157
- Testing
- Anrotinib plus Tirelizumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Head And Neck Cancer
Testing Accountability in Patient Adherence
The goal of this research study is to look for factors that influence whether or not head and neck cancer patients follow the swallowing exercises that they are asked to perform while receiving radiation treatment.
- Trial name
- NCT01844557
- Testing
- Swallowing Exercises, Symptom Inventory, Questionnaires
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- M.D. Anderson Cancer Center
Oral Cancer, Laryngeal Cancer
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis
The purpose of this study is to investigate the role of lymphangiogenesis in the metastasis of head and neck cancer.
- Conditions
- Oral Cancer, Laryngeal Cancer, Hypopharyngeal Cancer
- Trial name
- NCT00173381
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Surgical Wound Infection, Head and Neck Neoplasms
Prophylactic Antibiotic Duration in Head and Neck Cancer Surgery (PROTECT-HN Trial)
The goal of this clinical trial is to learn whether giving antibiotics for 7 days after surgery, instead of the usual 24 hours, lowers the chance of wound infection in adults having major surgery for mouth or throat cancer.
- Conditions
- Surgical Wound Infection, Head and Neck Neoplasms, Oral Cancer Neoplasms, Pharyngeal Neoplasms
- Trial name
- PROTECT-HN (NCT07851857)
- Testing
- Ampicillin/Sulbactam 24-Hour Postoperative Prophylaxis, Ampicillin/Sulbactam 7-Day Postoperative Prophylaxis
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- AC Camargo Cancer Center
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer.
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05172245
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 18 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer (Post Prostatectomy), Anal Cancer
Assessment of New Radiation Oncology Technologies and Treatments
The Trans Tasman Radiation Oncology Group (TROG) has been commissioned by the Department of Health and Ageing to undertake a project to assess new Radiation Oncology Technology and Treatments.
- Conditions
- Prostate Cancer (Post Prostatectomy), Anal Cancer, Nasopharyngeal Cancer, Intermediate Risk Prostate Cancer
- Trial name
- ANROTAT (NCT01379872)
- Testing
- Non-Interventional Study
- Where
- 15 sites in Australia
- Volunteers
- 138 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Nasopharyngeal Carcinoma, Brain Necrosis
Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
It is hypothesized that excessive generation of free radicals involves in the pathogenesis of radiation-induced brain necrosis. This study therefore evaluated the effect of free radical scavenger, edaravone, on radiation-induced…
- Trial name
- NCT01865201
- Testing
- Edaravone, Common fundamental management
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma, Sintilimab
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
The program aims to enroll patients with stage high risk (AJCC 8th, T3-4N2-3M0) . Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and…
- Trial name
- NCT05707819
- Testing
- Sintilimab (PD-1 Antibody)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Human Papilloma Virus, HPV
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the…
- Conditions
- Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT05108870
- Testing
- HB-201, HB-202, Carboplatin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Dysphagia
Pharyngocise Dose Response Study
In this study supported by an American Cancer Society grant, the investigators are evaluating two levels of swallowing exercise intensity on the maintenance of swallowing muscles and their function in Head/Neck cancer patients…
- Trial name
- NCT01279837
- Testing
- Pharyngocise
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Florida
Head and Neck Cancer
S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00017173
- Testing
- Ad5CMV-p53 gene, cisplatin, conventional surgery
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- SWOG Cancer Research Network
Nasopharyngeal Carcinoma, Adverse Effect of Radiation Therapy
Treatment of Bevacizumab Followed by Steroid in RN
Treatment of bevacizumab followed by steroid may have a better effect on patients with radiation-induced brain injury.This randomized trial aims to investigate whether treatment of bevacizumab followed by steroid may alleviate…
- Conditions
- Nasopharyngeal Carcinoma, Adverse Effect of Radiation Therapy, Brain Injuries
- Trial name
- NCT04553510
- Testing
- Bevacizumab and steroid
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma
Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients
Endemic nasopharyngeal carcinoma (NPC) is invariably associated with Epstein-barr virus (EBV) infection. Plasma EBV DAN detected by polymerase chain reaction (PCR)-based assays can provide important informations of disease…
- Trial name
- NCT03855020
- Testing
- Plasma EBV DNA
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Head and Neck Cancer
Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy
How does plasma Epstein-Barr Virus (EBV) DNA level change during definitive radiation therapy for nasopharyngeal carcinoma (NPC) in the teenage and young adult cohort and does it correlate with outcomes?
- Conditions
- Nasopharyngeal Carcinoma, Head and Neck Cancer, Nasopharyngeal Cancer, Epstein-Barr Virus
- Trial name
- ClearED (NCT06480903)
- Volunteers
- 10 people
- Sponsor
- The Christie NHS Foundation Trust
Esophageal Cancer
Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus
In this study, a newly designed and FDA approved fully covered metal stents will be used to palliate 20 patients with malignant lesion of the esophagus.
- Trial name
- NCT01301495
- Testing
- HANAROSTENT TM covered Esophageal Stent
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.